Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
Published inOnkologie, vol. 33, no. 6, p. 295-299
Publication date2010
Abstract
Keywords
- Antineoplastic Combined Chemotherapy Protocols/adverse effects/ therapeutic use
- Camptothecin/administration & dosage/adverse effects/analogs & derivatives
- Colorectal Neoplasms/ drug therapy/pathology
- Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
- Disease-Free Survival
- Female
- Fluorouracil/administration & dosage/adverse effects/analogs & derivatives
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis/pathology
- Neoplasm Staging
- Organoplatinum Compounds/administration & dosage/adverse effects
Affiliation
Research group
Citation (ISO format)
VON MOOS, Roger et al. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). In: Onkologie, 2010, vol. 33, n° 6, p. 295–299. doi: 10.1159/000313598
Main files (1)
Article
Identifiers
- PID : unige:21379
- DOI : 10.1159/000313598
- PMID : 20523092
ISSN of the journal0378-584X